Cerecor Inc (CERC) Major Shareholder Buys $519,554.00 in Stock

Cerecor Inc (NASDAQ:CERC) major shareholder Armistice Capital Master Fund acquired 125,800 shares of the business’s stock in a transaction on Wednesday, October 24th. The stock was acquired at an average price of $4.13 per share, with a total value of $519,554.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Tuesday, October 9th, Armistice Capital Master Fund bought 29,600 shares of Cerecor stock. The shares were purchased at an average price of $4.34 per share, with a total value of $128,464.00.
  • On Thursday, September 27th, Armistice Capital Master Fund bought 20,400 shares of Cerecor stock. The shares were purchased at an average price of $4.64 per share, with a total value of $94,656.00.
  • On Friday, August 17th, Armistice Capital Master Fund bought 1,000,000 shares of Cerecor stock. The shares were purchased at an average price of $3.91 per share, with a total value of $3,910,000.00.
  • On Tuesday, July 31st, Armistice Capital Master Fund bought 2,855 shares of Cerecor stock. The shares were purchased at an average price of $4.25 per share, with a total value of $12,133.75.
  • On Friday, July 27th, Armistice Capital Master Fund bought 28,926 shares of Cerecor stock. The shares were purchased at an average price of $4.41 per share, with a total value of $127,563.66.

CERC stock opened at $3.94 on Friday. The firm has a market cap of $162.72 million, a PE ratio of 16.67 and a beta of 1.32. Cerecor Inc has a twelve month low of $0.93 and a twelve month high of $5.74. The company has a quick ratio of 0.54, a current ratio of 0.62 and a debt-to-equity ratio of 0.75.



Cerecor (NASDAQ:CERC) last released its earnings results on Thursday, August 9th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $4.79 million during the quarter, compared to the consensus estimate of $4.50 million. Cerecor had a return on equity of 43.87% and a net margin of 15.71%. On average, equities research analysts predict that Cerecor Inc will post -0.55 earnings per share for the current fiscal year.

Separately, ValuEngine upgraded Cerecor from a “hold” rating to a “buy” rating in a research report on Wednesday, August 29th.

Several hedge funds have recently added to or reduced their stakes in CERC. Northern Trust Corp raised its position in shares of Cerecor by 182.0% during the first quarter. Northern Trust Corp now owns 31,506 shares of the company’s stock worth $135,000 after acquiring an additional 20,333 shares during the last quarter. Spark Investment Management LLC bought a new stake in shares of Cerecor during the second quarter worth $288,000. Finally, BlackRock Inc. raised its position in shares of Cerecor by 630.4% during the second quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock worth $120,000 after acquiring an additional 23,752 shares during the last quarter. Institutional investors own 41.61% of the company’s stock.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

Featured Story: How to use beta for portfolio diversification

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply